Shares of biotechnology company Amyris (NASDAQ:AMRS) have tanked nearly 17% at the time of writing today after it initiated a transformation program to improve its capital structure, liquidity, and costs.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The company’s Board has roped in the Business Recovery Services unit of PricewaterhouseCoopers (PwC) and set up a Restructuring Committee under this program. The development comes after Amyris undertook a strategic review of its cost structure and is now aiming for $250 million in planned cost reductions.
Additionally, the company has also entered into loan amendments with its principal secured lenders and in a secured term loan facility with Anesma Group. The move has resulted in $50 million being available to Amyris and it plans to use the funds for working capital and general corporate purposes.
Overall, the Street has a $1.88 consensus price target on Amyris alongside a Moderate Buy consensus rating.
Shares of the company have plummeted nearly 57% over the past six months while short interest in the stock still remains sky-high at nearly 22% at present.
Read full Disclosure